- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.11. | Sera Prognostics, Inc.: Sera Prognostics Reports Third Quarter 2024 Financial Results | 10 | PR Newswire | SALT LAKE CITY, Nov. 6, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health... ► Artikel lesen | |
| SERA PROGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 06.11. | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11. | SERA PROGNOSTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 10.09. | Sera Prognostics CEO sells shares worth $189,893 | 1 | Investing.com | ||
| 08.08. | Sera Prognostics director sells shares worth $749 | 1 | Investing.com | ||
| 08.08. | Sera Prognostics CIO sells over $37k in company stock | 1 | Investing.com | ||
| 08.08. | Sera Prognostics executive sells $37k in company stock | 1 | Investing.com | ||
| 08.08. | Sera Prognostics executive sells shares worth over $32,000 | 1 | Investing.com | ||
| 07.08. | Sera Prognostics files $100M mixed securities shelf | 1 | Seeking Alpha | ||
| 07.08. | SERA PROGNOSTICS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.08. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08. | Sera Prognostics, Inc.: Sera Prognostics Reports Second Quarter 2024 Financial Results | 59 | PR Newswire | SALT LAKE CITY, Aug. 7, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker... ► Artikel lesen | |
| 01.07. | Sera Prognostics joins Russell 2000, Russell 3000 indexes | 1 | Seeking Alpha | ||
| 06.06. | SERA PROGNOSTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2024 Financial Results | 170 | PR Newswire | SALT LAKE CITY, May 8, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker... ► Artikel lesen | |
| 20.03. | Sera Prognostics, Inc.: Sera Prognostics Reports Fourth Quarter 2023 Financial Results | 182 | PR Newswire | SALT LAKE CITY, March 20, 2024 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 0,900 | -21,74 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| NANOREPRO | 1,600 | +3,90 % | NanoRepro Aktie: Alles im Blick? | Die NanoRepro AG, ein führender Entwickler medizinischer Selbsttests, zeigt sich trotz wirtschaftlicher Herausforderungen widerstandsfähig. Am 09. November 2024 notierte die Aktie bei 1,64 EUR, unverändert... ► Artikel lesen | |
| OCUGEN | 0,860 | -1,21 % | Ocugen Receives Orphan Medicinal Product Designation From EMA For OCU410ST | ||
| VIKING THERAPEUTICS | 48,760 | -0,33 % | Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs | ||
| SCORPIUS | 0,050 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability | DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO")... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 2,780 | 0,00 % | COSCIENS Biopharma Inc. Reports Third Quarter 2024 Financial Results and Provides Update on Advancements with Merger Integration Process and Ongoing Development Programs | Continued execution on merger integration with Ceapro Inc. and advancements across business Company ended the quarter with US$20.0 million in cash TORONTO, ONTARIO, Nov. 12, 2024 (GLOBE... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,384 | +3,78 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,000 | +0,98 % | BioCryst Pharmaceuticals, Inc.: BioCryst Launches ORLADEYO (berotralstat) in Ireland | ||
| REDHILL BIOPHARMA | 6,370 | -6,32 % | RedHill Biopharma Ltd.: New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality | Data, from a post hoc analysis of the randomized, placebo-controlled, double-blind phase 2/3 study of oral opaganib in COVID-19 pneumonia, showing a 62% reduction in mortality and a 21% improvement... ► Artikel lesen | |
| VAXART | 0,574 | -0,61 % | Vaxart Inc reports results for the quarter ended September 30 - Earnings Summary | ||
| IBIO | 2,270 | 0,00 % | iBio, Inc.: iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update | SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended... ► Artikel lesen | |
| ARBUTUS BIOPHARMA | 3,294 | +0,61 % | Arbutus Biopharma Corporation: Arbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon | 50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the IM-PROVE I Phase 2a clinical trial Overall, in Cohort A1, 25% of patients achieved... ► Artikel lesen | |
| ALDEYRA | 4,480 | -0,71 % | Aldeyra Therapeutics, Inc.: Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference | Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases,... ► Artikel lesen | |
| MANNKIND | 6,692 | +2,58 % | MannKind Corp. Q3 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - MannKind Corp. (MNKD) revealed a profit for its third quarter that increased from last year and beat the Street estimates.The company's earnings totaled $11.55 million... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,000 | -0,83 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest |
Das Unternehmen SERA PROGNOSTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 6,080 Euro und damit +0,75 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SERA PROGNOSTICS INC finden Sie auf Wallstreet Online.
